Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the month of December 2021, specifically dated December 22, 2021. The report discloses corporate governance events rather than operational or financial performance data.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely to report share acquisition activities by company insiders.
Material Changes
The material events disclosed in this period are:
- Acquisition of shares by the Executive Chairman.
- Acquisition of shares by one of the company's directors.
These transactions were announced via press releases lodged with the Australian Securities Exchange (ASX) and are attached as Exhibits 99.1 and 99.2.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is a procedural report of insider trading activity.
Investor Verification Checklist
- Verify the specific number of shares acquired by the Executive Chairman and the director in the attached press releases (Exhibits 99.1 and 99.2).
- Confirm the purchase price per share and total transaction value for these insider acquisitions.
- Review the company's most recent Form 20-F for actual financial performance metrics, as this 6-K does not contain them.